APA (7th ed.) Citation

N, H., Z, W., M, L., D, G., C, J., Y, C., . . . X, S. (2026). Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: A literature review. Frontiers in immunology, 17, 1780459. https://doi.org/10.3389/fimmu.2026.1780459

Chicago Style (17th ed.) Citation

N, Hu, et al. "Multi-omics Biomarkers for Predicting Resistance, Hyperprogression, and Immune-related Toxicity During PD-1/PD-L1 Therapy in Lung Cancer: A Literature Review." Frontiers in Immunology 17 (2026): 1780459. https://doi.org/10.3389/fimmu.2026.1780459.

MLA (9th ed.) Citation

N, Hu, et al. "Multi-omics Biomarkers for Predicting Resistance, Hyperprogression, and Immune-related Toxicity During PD-1/PD-L1 Therapy in Lung Cancer: A Literature Review." Frontiers in Immunology, vol. 17, 2026, p. 1780459, https://doi.org/10.3389/fimmu.2026.1780459.